211 related articles for article (PubMed ID: 17970640)
1. Fatty acid synthase inhibitors: new directions for oncology.
Kridel SJ; Lowther WT; Pemble CW
Expert Opin Investig Drugs; 2007 Nov; 16(11):1817-29. PubMed ID: 17970640
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents?
Lupu R; Menendez JA
Curr Pharm Biotechnol; 2006 Dec; 7(6):483-93. PubMed ID: 17168665
[TBL] [Abstract][Full Text] [Related]
3. Recent Advances in the Development of Fatty Acid Synthase Inhibitors as Anticancer Agents.
Singh S; Karthikeyan C; Moorthy NSHN
Mini Rev Med Chem; 2020; 20(18):1820-1837. PubMed ID: 32781957
[TBL] [Abstract][Full Text] [Related]
4. Molecular Pathways: Fatty Acid Synthase.
Jones SF; Infante JR
Clin Cancer Res; 2015 Dec; 21(24):5434-8. PubMed ID: 26519059
[TBL] [Abstract][Full Text] [Related]
5. [Fatty acid synthase: a new anti-tumor target].
Puig T; Porta R; Colomer R
Med Clin (Barc); 2009 Mar; 132(9):359-63. PubMed ID: 19268984
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in targeting the fatty acid biosynthetic pathway using fatty acid synthase inhibitors.
Angeles TS; Hudkins RL
Expert Opin Drug Discov; 2016 Dec; 11(12):1187-1199. PubMed ID: 27701891
[TBL] [Abstract][Full Text] [Related]
7. Diacylglycerol Metabolism and Signaling Is a Driving Force Underlying FASN Inhibitor Sensitivity in Cancer Cells.
Benjamin DI; Li DS; Lowe W; Heuer T; Kemble G; Nomura DK
ACS Chem Biol; 2015 Jul; 10(7):1616-23. PubMed ID: 25871544
[TBL] [Abstract][Full Text] [Related]
8. Discovery and optimization of novel piperazines as potent inhibitors of fatty acid synthase (FASN).
Martin MW; Lancia DR; Li H; Schiller SER; Toms AV; Wang Z; Bair KW; Castro J; Fessler S; Gotur D; Hubbs SE; Kauffman GS; Kershaw M; Luke GP; McKinnon C; Yao L; Lu W; Millan DS
Bioorg Med Chem Lett; 2019 Apr; 29(8):1001-1006. PubMed ID: 30803804
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms of fatty acid synthase (FASN)-mediated resistance to anti-cancer treatments.
Wu X; Qin L; Fako V; Zhang JT
Adv Biol Regul; 2014 Jan; 54():214-21. PubMed ID: 24080588
[TBL] [Abstract][Full Text] [Related]
10. Fatty acid synthase - Modern tumor cell biology insights into a classical oncology target.
Buckley D; Duke G; Heuer TS; O'Farrell M; Wagman AS; McCulloch W; Kemble G
Pharmacol Ther; 2017 Sep; 177():23-31. PubMed ID: 28202364
[TBL] [Abstract][Full Text] [Related]
11. Fatty acid synthase as a potential therapeutic target in cancer.
Flavin R; Peluso S; Nguyen PL; Loda M
Future Oncol; 2010 Apr; 6(4):551-62. PubMed ID: 20373869
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effect of emodin on fatty acid synthase, colon cancer proliferation and apoptosis.
Lee KH; Lee MS; Cha EY; Sul JY; Lee JS; Kim JS; Park JB; Kim JY
Mol Med Rep; 2017 Apr; 15(4):2163-2173. PubMed ID: 28260110
[TBL] [Abstract][Full Text] [Related]
13. A novel small-molecule fatty acid synthase inhibitor with antitumor activity by cell cycle arrest and cell division inhibition.
Qu H; Shan K; Tang C; Cui G; Fu G; Qi Y; Cui J; Li J; Wang R; Feng N; Chen YQ
Eur J Med Chem; 2021 Jul; 219():113407. PubMed ID: 33901805
[TBL] [Abstract][Full Text] [Related]
14. Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase.
Fako VE; Wu X; Pflug B; Liu JY; Zhang JT
J Med Chem; 2015 Jan; 58(2):778-84. PubMed ID: 25513712
[TBL] [Abstract][Full Text] [Related]
15. A Cellular Assay for Inhibitors of the Fatty Acid Biosynthetic Pathway Using Scintillating Microplates.
Ung T; Mason JL; Robinson RG; Spais CM; Ator MA; Angeles TS
Assay Drug Dev Technol; 2015 Jun; 13(5):285-92. PubMed ID: 26125659
[TBL] [Abstract][Full Text] [Related]
16. Review on target domains and natural compound-based inhibitors of fatty acid synthase for anticancer drug discovery.
Pulla LSS; Begum Ahil S
Chem Biol Drug Des; 2021 Nov; 98(5):869-884. PubMed ID: 34459114
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the thioesterase activity of human fatty acid synthase by 1,4- and 9,10-diones.
Odens H; Lowther T; Kridel S; Watts L; Filipponi L; Schmitt J
Chem Pharm Bull (Tokyo); 2014; 62(9):933-6. PubMed ID: 25177021
[TBL] [Abstract][Full Text] [Related]
18. Fatty acid synthase (FASN) as a therapeutic target in breast cancer.
Menendez JA; Lupu R
Expert Opin Ther Targets; 2017 Nov; 21(11):1001-1016. PubMed ID: 28922023
[TBL] [Abstract][Full Text] [Related]
19. Fatty Acid Synthase: An Emerging Target in Cancer.
Fhu CW; Ali A
Molecules; 2020 Aug; 25(17):. PubMed ID: 32872164
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer.
Giró-Perafita A; Palomeras S; Lum DH; Blancafort A; Viñas G; Oliveras G; Pérez-Bueno F; Sarrats A; Welm AL; Puig T
Clin Cancer Res; 2016 Sep; 22(18):4687-97. PubMed ID: 27106068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
